Roussel UCLAF : profits en hausse de 11%. l'Humanité. February 18, 1997. Hoechst AG: Roussel Uclaf unit posts net profit increase of 90%. The Wall Street Journal. February 18, 1997: A6. 1996: $3.01 billion sales, $339.5 million net profit
lemonde.fr
Aizicovici, Francine. Le désarroi des salariés. Le Monde. March 7, 1994. headquarters moved to Romainville in April 1995 after 40 years at 35 Boulevard des Invalides, Paris.
Eder, Richard. Birth control: 4-day pill is promising in early test. The New York Times. April 20, 1982: C1 [2023-01-31]. (原始内容存档于2016-06-25). Herrmann, Walter; Wyss, Rolf; Riondel, Anne; Philibert, Daniel; Teutsch, Georges; Sakiz, Edouard; Baulieu, Étienne-Émile. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. Comptes Rendus de l'Académie des Sciences, Série III. May 17, 1982, 294 (18): 933–8. PMID 6814714.
Smith, W. Great Britain second country to allow use of RU-486. Plan Parent Eur. September 1991, 20 (2): 20. PMID 12284548.
RU 486 licensed in Sweden. IPPF Med Bull. December 1992, 26 (6): 6. PMID 12346922.
Eder, Richard. Birth control: 4-day pill is promising in early test. The New York Times. April 20, 1982: C1 [2023-01-31]. (原始内容存档于2016-06-25). Herrmann, Walter; Wyss, Rolf; Riondel, Anne; Philibert, Daniel; Teutsch, Georges; Sakiz, Edouard; Baulieu, Étienne-Émile. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. Comptes Rendus de l'Académie des Sciences, Série III. May 17, 1982, 294 (18): 933–8. PMID 6814714.
Newman, Barry. Drug dilemma: among those wary of abortion pill is maker's parent firm; Germany's Hoechst is facing pressure from Clinton to sell RU-486 in U.S.. The Wall Street Journal. February 22, 1993: A1. F.D.A. says company delays abortion pill. The New York Times. Associated Press. April 16, 1993: A14 [2023-01-31]. (原始内容存档于2016-08-03). Jouzaitis, Carol. Abortion pill battle surprises French firm. Chicago Tribune. October 17, 1994: 1 (Business) [2023-01-31]. (原始内容存档于2013-02-18).
Moore, Stephen D.; Kamm, Thomas; Fleming, Charles. Hoechst to seek rest of Roussel-Uclaf; expected $3.04 billion offer would add to the wave of drug-sector linkups. The Wall Street Journal. December 11, 1996: A3. Marshall, Matt. Hoechst offers to pay $3.6 billion for rest of Roussel. The Wall Street Journal. December 11, 1996: A8. Bloomberg Business News. Hoechst to buy rest of Roussel. The New York Times. December 11, 1996: D4 [2023-01-31]. (原始内容存档于2016-06-25).
Newman, Barry. Drug dilemma: among those wary of abortion pill is maker's parent firm; Germany's Hoechst is facing pressure from Clinton to sell RU-486 in U.S.. The Wall Street Journal. February 22, 1993: A1. F.D.A. says company delays abortion pill. The New York Times. Associated Press. April 16, 1993: A14 [2023-01-31]. (原始内容存档于2016-08-03). Jouzaitis, Carol. Abortion pill battle surprises French firm. Chicago Tribune. October 17, 1994: 1 (Business) [2023-01-31]. (原始内容存档于2013-02-18).
Eder, Richard. Birth control: 4-day pill is promising in early test. The New York Times. April 20, 1982: C1 [2023-01-31]. (原始内容存档于2016-06-25). Herrmann, Walter; Wyss, Rolf; Riondel, Anne; Philibert, Daniel; Teutsch, Georges; Sakiz, Edouard; Baulieu, Étienne-Émile. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. Comptes Rendus de l'Académie des Sciences, Série III. May 17, 1982, 294 (18): 933–8. PMID 6814714.
Newman, Barry. Drug dilemma: among those wary of abortion pill is maker's parent firm; Germany's Hoechst is facing pressure from Clinton to sell RU-486 in U.S.. The Wall Street Journal. February 22, 1993: A1. F.D.A. says company delays abortion pill. The New York Times. Associated Press. April 16, 1993: A14 [2023-01-31]. (原始内容存档于2016-08-03). Jouzaitis, Carol. Abortion pill battle surprises French firm. Chicago Tribune. October 17, 1994: 1 (Business) [2023-01-31]. (原始内容存档于2013-02-18).
Moore, Stephen D.; Kamm, Thomas; Fleming, Charles. Hoechst to seek rest of Roussel-Uclaf; expected $3.04 billion offer would add to the wave of drug-sector linkups. The Wall Street Journal. December 11, 1996: A3. Marshall, Matt. Hoechst offers to pay $3.6 billion for rest of Roussel. The Wall Street Journal. December 11, 1996: A8. Bloomberg Business News. Hoechst to buy rest of Roussel. The New York Times. December 11, 1996: D4 [2023-01-31]. (原始内容存档于2016-06-25).
Roussel Uclaf disappears, giving way to Hoechst Marion Russell. Chemical Business NewsBase (Cambridge: Royal Society of Chemistry). October 14, 1997. 2nd largest pharmaceutical company (after Rhône-Poulenc(英语:Rhône-Poulenc) and ahead of Sanofi)